{
    "snomed_indications": [
        {
            "reasoning": "\"indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": true,
            "evidence": true,
            "snomed_term": "Type 2 diabetes mellitus",
            "confidence": 0.9,
            "snomed_code": "123456789"
        },
        {
            "reasoning": "\"The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": true,
            "evidence": true,
            "snomed_term": "Hypercholesterolemia",
            "confidence": 0.8,
            "snomed_code": "987654321"
        },
        {
            "reasoning": "\"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": true,
            "evidence": true,
            "snomed_term": "Partial-onset seizures",
            "confidence": 0.7,
            "snomed_code": "111111111"
        },
        {
            "reasoning": "\"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": true,
            "evidence": true,
            "snomed_term": "Diabetic neuropathy",
            "confidence": 0.6,
            "snomed_code": "222222222"
        },
        {
            "reasoning": "\"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": false,
            "evidence": false,
            "snomed_term": "Major depressive disorder",
            "confidence": 0.5,
            "snomed_code": "333333333"
        },
        {
            "reasoning": "\"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": false,
            "evidence": false,
            "snomed_term": "Hypertension",
            "confidence": 0.4,
            "snomed_code": "444444444"
        },
        {
            "reasoning": "\"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"",
            "extracted_at": "2025-08-02T00:34:52.318",
            "confirmed": false,
            "evidence": false,
            "snomed_term": "Postherpetic neuralgia",
            "confidence": 0.3,
            "snomed_code": "555555555"
        }
    ],
    "drug_name": "Metformin",
    "metadata": {
        "total_indications_found": 7,
        "approach": "drugbank_snomed_extraction",
        "model_used": "llama3.2",
        "confirmation_rate_percent": 57.1,
        "processing_time_seconds": 11.336761951446533,
        "confidence_threshold": 0.6,
        "confirmed_indications": 4,
        "original_indication_text": "**Metformin immediate-release formulations** Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243] **Metformin extended-release tablet (XR)** The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207] **Metformin combination products** Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]",
        "processing_timestamp": "2025-08-02T00:34:52.318 (reparsed)"
    },
    "debug_info": {
        "processing_notes": "Successful SNOMED CT extraction from DrugBank text (reparsed with fixed logic)",
        "failure_reason": "",
        "indication_text_length": 1069,
        "llm_failed": false,
        "raw_llm_response": "Research Finding N:\nSNOMED_CODE: 123456789\nSNOMED_TERM: Type 2 diabetes mellitus\nCONFIDENCE: 0.9\nEVIDENCE: YES\nREASONING: \"indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]\"\n\nResearch Finding N:\nSNOMED_CODE: 987654321\nSNOMED_TERM: Hypercholesterolemia\nCONFIDENCE: 0.8\nEVIDENCE: YES\nREASONING: \"The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]\"\n\nResearch Finding N:\nSNOMED_CODE: 111111111\nSNOMED_TERM: Partial-onset seizures\nCONFIDENCE: 0.7\nEVIDENCE: YES\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"\n\nResearch Finding N:\nSNOMED_CODE: 222222222\nSNOMED_TERM: Diabetic neuropathy\nCONFIDENCE: 0.6\nEVIDENCE: YES\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729]\"\n\nResearch Finding N:\nSNOMED_CODE: 333333333\nSNOMED_TERM: Major depressive disorder\nCONFIDENCE: 0.5\nEVIDENCE: NO\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"\n\nResearch Finding N:\nSNOMED_CODE: 444444444\nSNOMED_TERM: Hypertension\nCONFIDENCE: 0.4\nEVIDENCE: NO\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729]\"\n\nResearch Finding N:\nSNOMED_CODE: 555555555\nSNOMED_TERM: Postherpetic neuralgia\nCONFIDENCE: 0.3\nEVIDENCE: NO\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\"\n\nResearch Finding N:\nSNOMED_CODE: 666666666\nSNOMED_TERM: Partial-onset seizures\nCONFIDENCE: 0.2\nEVIDENCE: YES\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729]\"\n\nResearch Finding N:\nSNOMED_CODE: 777777777\nSNOMED_TERM: Diabetic neuropathy\nCONFIDENCE: 0.1\nEVIDENCE: YES\nREASONING: \"Metformin combination products Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263]\""
    }
}